Current Clinical Trials

Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT00769379
Title: NSABP B43, A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Lowry MD, Philip
Sponsor: CALGB
Indentifier #: NCT01150045
Title: CALGB 80702, A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT01275677
Title: NSABP B47, A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Department: Oncology
Diagnosis: Gastrointestinal - Liver
Principal Investigator:
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT01015833
Title: CALGB 80802, Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients with Advanced Hepatocellular Carcinoma (HCC)

Pages